What is FENC's P/E ratio?

Fennec Pharmaceuticals Inc (FENC) currently trades at a P/E ratio of 1,712.66.

Fennec Pharmaceuticals Inc reports a Return on Equity (ROE) of -22.23%.

What is FENC's dividend yield?

Fennec Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is FENC's Quality Score?

Our AI rates FENC's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy FENC?

Our AI Timing Score for FENC is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does FENC belong to?

Fennec Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Fennec Pharmaceuticals Inc (FENC) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

FENC AI Analysis Summary

Our AI summary for FENC: Fennec Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1,712.66, ROE of -22.23%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

FENC

Fennec Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 79

USD 9.57

-0.34 (-3.43%) Day Change

Watchlist Portfolio Compare Chart

1,712.66

P/E

0.91

D/E

-22.2%

ROE

-11.7%

ROA

0.00%

Div Yield

2.70

PEG

FENNEC PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 9.57 Price -0.34 (-3.43%) Day Change	NEWS SCORE: 79

FENC, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	79
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	9.57
PBV / Sector	9.14 / 5.20
Earning Per Share	-0.23

PE / Sector	1,712.66 / 19.97 GREAT
PEG or PE/Growth / Sector	2.70 / 1.22
Average 1M Daily Value	1.47 M GREAT
Average 1W Daily Value	0.94 M GREAT

Timing Factors

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-16.42 / 98.71
NPM Average (%) / Sector	-331.91 / -1,721.76
NPM Change Average (%) / Sector	515.12 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-11.66 / 27.02
ROA Average (%) / Sector	-34.86 / -368.17
ROA Change Average (%) / Sector	296.63 / 5,404.12 GREAT
ROE (%) / Sector	-22.23 / 3.47
ROE Average (%) / Sector	203.71 / 6.51 GREAT
ROE Change Average (%) / Sector	-168.49 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:50
Symbol	FENC
Name	FENNEC PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	34.74 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	344.24 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Phone: 919 636 4530

Website: https://www.fennecpharma.com

Sector: Healthcare >> Biotechnology

Description: Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.